Clinical trials: H1N1/Influenza Infection
Virus Diseases, Respiratory Tract Diseases
Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older
The primary safety objective of this study is to assess the safety of split- virion inactivated H1N1 vaccine with and without adjuvant when administered at the 7.5,15 or 30 mcg dose.
- Conditions
- Virus Diseases, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
- Trial name
- NCT00975572
- Testing
- split-virion, non-adjuvanted H1N1 vaccine of 30 μg, Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg, Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg
- Where
- China
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
Sanofi H1N1 + TIV - Adults and Elderly
The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine against the 2009 H1N1 virus.
- Trial name
- NCT00943878
- Testing
- Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine
- Where
- 5 sites in United States
- Volunteers
- 805 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Viral, Influenza in Humans
Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu
The H1N1 flu pandemic is one of the major infectious threat of the past half century. it is rapidly progressing worldwide and a substantial number of patients get severe H1N1 related pneumonia that requires mechanical ventilation…
- Trial name
- CORTIFLU (NCT01014364)
- Testing
- hydrocortisone, isotonic saline
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University of Versailles
Influenza, Pandemic Influenza
Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine
The purpose of this observational study, which will be initiated as soon as the licensed H1N1 Pandemic Influenza Vaccine is used in a mass vaccination campaign, is to estimate the incidence of any medically-attended adverse…
- Trial name
- NCT00950456
- Testing
- H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)
- Where
- 17 sites in Austria
- Volunteers
- 3,216 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 18 to 64 years of age.
- Trial name
- NCT01008956
- Testing
- GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Pregnancy
"COhort Study on A/H1N1 FLU During PREGnancy"
The purpose of this study is to measure the incidence of A/H1N1 Influenza infection in the mother and her child and to identify the determinants in pregnant women during pandemic period in three public maternities in Paris…
- Trial name
- COFLUPREG (NCT01192737)
- Where
- 3 sites in France
- Volunteers
- 919 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Influenza
Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
The primary objective of this observational, comparative safety study is to evaluate the safety of the Novartis Pandemic Influenza A (H1N1) vaccine in pregnant women and their off spring, followed for up to 3 months of age as…
- Trial name
- NCT01037829
- Testing
- Non-intervention observational study
- Where
- 17 sites in Argentina, Italy and 1 more
- Volunteers
- 4,529 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
HIV-1 Infection, Cancer
Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients
The purpose of this study is to evaluate the immunogenicity and safety of an adjuvanted A(H1N1)v influenza vaccine in HIV-infected and immunosuppressed patients after one and two injections.
- Conditions
- HIV-1 Infection, Cancer, Immunosuppression
- Trial name
- NCT01017172
- Testing
- serologic testing
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Goethe University
Influenza
Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM
This study is designed to assess the immunogenicity, reactogenicity and safety following vaccination with GSK Biologicals' FluarixTM vaccine in children who have previously been vaccinated with one dose of PandemrixTM at the age…
- Trial name
- NCT01190215
- Testing
- FluarixTM, HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)
- Where
- Finland
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years
The purpose of this study is to show that vaccination with a single dose of GSK Biologicals' pandemic H1N1 vaccine results in an immune response that meets or exceeds European Medicines Agency (EMEA) Committee for Medicinal…
- Trial name
- NCT01035749
- Testing
- GSK Biologicals' Influenza investigational vaccine GSK2340274A, GSK Biologicals' Influenza investigational vaccine GSK2340273A
- Where
- 9 sites in Estonia, Slovakia
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Swine-origin A/H1N1 Influenza
Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT01040078
- Testing
- 7.5ug H1N1 Influenza vaccine, 15ug H1N1 vaccine, seasonal influenza vaccine
- Where
- 3 sites in China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Hepatitis B
Antigen-specific Immune Response to Hepatitis B Virus in Utero
This study aims to gain an understanding of the key components of the immune response to hepatitis B present in cord blood of HBV infected mothers.
- Trial name
- NCT00845403
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Influenza, Influenza, Human
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
The purpose of this study is to evaluate the body's immune response at different time points to an FDA-approved seasonal influenza vaccine.
- Conditions
- Influenza, Influenza, Human, Vaccine Reaction, Influenza A
- Trial name
- KIRV (NCT03743688)
- Testing
- Influenza Vaccine Recipients
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Influenza
Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1) : Multi-centre, Prospective, Randomized Controlled Study
The purpose of this study is to determine whether Chinese medicinal herbs are effective and safe for treating novel influenza A (H1N1) infection.
- Trial name
- NCT00935194
- Testing
- oseltamivir, blank, chinese medicinal herbs
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Capital Medical University
Healthy, Immunosuppressed
Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva
This study aims to identify clinical symptoms and outcomes, as well as response to anti-viral treatment in children living in Geneva, with influenza A/ H1N1 infection during the current pandemic.
- Conditions
- Healthy, Immunosuppressed, Asthmatic, Neuromuscular Diseases
- Trial name
- NCT01022931
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University Hospital, Geneva
Influenza, HIV Infections
Immunogenicity of Novel H1N1 Vaccination Among HIV-Infected Compared to HIV-Uninfected Persons
The purpose of this research is to determine the effectiveness of the novel H1Nl influenza (inactivated/killed formulation) vaccine among both HIV-infected and HIV-uninfected persons.
- Trial name
- NCT00996970
- Where
- 3 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Influenza
CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in healthy adult and elderly populations.
- Trial name
- NCT00943488
- Testing
- Inactivated H1N1 Vaccine
- Where
- 4 sites in United States
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old
This study is designed to characterize the safety and immunogenicity of pandemic influenza (H1N1) candidate vaccines GSK2340274A and GSK234072A in children 3 to less than 10 years old.
- Trial name
- NCT01161160
- Testing
- GSK Biologicals' GSK2340274A (two different formulations), GSK Biologicals' - GSK2340272A
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Sanofi Pasteur, TIV + H1N1, Pediatric Population
The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine against the 2009 H1N1 virus.
- Trial name
- NCT00943202
- Testing
- Inactivated H1N1 Vaccine, Trivalent Inactivated Influenza Vaccine
- Where
- 8 sites in United States
- Volunteers
- 531 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)
This is study where medical record information will be collected as well as collection of excess biological samples.
- Trial name
- NCT01024673
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Pittsburgh